UBS downgraded Oscar Health (NYSE:OSCR) from Neutral to Sell, cutting its price target to $11 from $15 due to rising concerns over the stability of the Public Health Insurance Exchanges and the company’s exposure to enrollment declines.
UBS now expects Oscar’s exchange enrollment to drop by at least 30% in 2026, a deeper cut than the prior forecast of 18%. The downgrade reflects growing uncertainty tied to the expiration of enhanced federal subsidies, which are set to roll off and could significantly reduce membership. The firm sees Oscar as unable to fully offset these losses through pricing adjustments, expecting only a 25% mitigation.
The broader exchange environment also poses risks. UBS anticipates major premium hikes from large competitors, which could introduce further enrollment volatility and create uncertainty around medical loss ratios (MLR). Additional enrollment pressures may come from new program integrity measures designed to tighten eligibility and reduce fraud.
While reductions in general and administrative expenses offer some cushion, UBS argues that Oscar’s stock requires a more stable exchange market to justify higher valuations. Without that, the firm sees downside risk outweighing potential upside in the near term.
